New Conjugates Based on N4-Hydroxycytidine with More Potent Antiviral Efficacy In Vitro than EIDD-2801 against SARS-CoV-2 and Other Human Coronaviruses

To improve the antiviral potency of β-D-N4-hydroxycytidine (NHC), the metabolite of a recently approved treatment for COVID-19, researchers developed a panel of NHC conjugates with lipophilic vectors and ester derivatives with amino- and carboxylic-acids.